---
title: "Radiopharm Theranostics advances 177Lu-RAD202 Phase 1 HEAT trial to 180 mCi dose cohort after DSMC review"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296479142.md"
description: "Radiopharm Theranostics advanced its Phase 1 HEAT trial of 177Lu-RAD202 to the 180 mCi dose cohort (Cohort 4) following a positive recommendation from the Data Safety Monitoring Committee. The trial targets patients with HER2-positive advanced solid tumors, building on earlier proof-of-concept data in breast cancer that demonstrated favorable safety and tumor targeting. This update reflects a safety review supporting continued dose escalation."
datetime: "2026-08-20T11:03:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296479142.md)
  - [en](https://longbridge.com/en/news/296479142.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296479142.md)
generator: "portal-rs"
---

# Radiopharm Theranostics advances 177Lu-RAD202 Phase 1 HEAT trial to 180 mCi dose cohort after DSMC review

-   Radiopharm Theranostics moved its Phase 1 HEAT trial of 177Lu-RAD202 into Cohort 4 following a positive DSMC recommendation. \* The trial will test a higher dose level in patients with HER2-positive advanced solid tumors, extending evaluation of the radiotherapeutic candidate. \* No new results were presented; the update reflects a safety review that supported continued dose escalation. \* Earlier diagnostic work in HER2-positive breast cancer patients showed proof-of-concept with favorable safety and tumor targeting, supporting further development. \* The HEAT study is running at clinical centers in Australia; the prior dose-level update was released on April 8, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200700PRIMZONEFULLFEED1001258433) on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [RADX.US](https://longbridge.com/en/quote/RADX.US.md)

## Related News & Research

- [Radiopharm Theranostics doses first patient in second cohort of RV-01 Phase 1/2a trial in B7-H3 solid tumors](https://longbridge.com/en/news/297032752.md)
- [Radiopharm schedules FDA end-of-Phase 2 meeting to align Phase 3 trial design for RAD101 brain metastases imaging agent](https://longbridge.com/en/news/296102289.md)
- [Jazz says FDA approves Ziihera combos for first-line HER2+ advanced gastroesophageal cancer](https://longbridge.com/en/news/297497068.md)
- [How Investors Are Reacting To BeOne Medicines (ONC) First-Line HER2-Positive GEA Immunotherapy Approval](https://longbridge.com/en/news/297146976.md)
- [Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering | KZIA Stock News](https://longbridge.com/en/news/297566493.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**